




2corex

Future cancer patients will be treated individually

**Nordnet Interview
02. March 2021**

**Fernando Andreu, CEO
Ole Thastrup, CSO**

70% of Cancer treatments still fail



On average the percentage of the population for whom a particular drug in a specific disease area was ineffective

IndiTreat[®] will become the global standard for Oncologists to individualize cancer treatment

- because cancer patients are individuals

Key messages

- 2cureX is meeting an unmet medical need in cancer
- Strong momentum in the 2cureX story
- The IndiTreat® test improves PFS (Progression Free Survival) in colorectal cancer
- Strengthening the executive Management team with international go-to-market expertise
- First IndiTreat® product to be rolled-out
- Strong commercial outlook for 2021-2023
- An attractive investment-case



Fernando Andreu
CEO



fa@2curex.com



Ole Thastrup
CSO



ot@2curex.com

Strong 2cureX News flow in Q1 2021



MAR 1



Press Releases Press Releases Regulatory

2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.

FEB 4



Press Releases Press Releases Regulatory

IndiTreat® selected to prestigious multinational ovarian cancer project.

JAN 28



Press Releases Press Releases Regulatory

2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO.

JAN 21



Press Releases

Last patient treated in the world's first interventional trial with 3D microtumors as guide for choice of cancer treatment.

JAN 5



Press Releases Press Releases Regulatory

2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO

-because cancer patients are individuals

2cureX is defined by a strong foundation



-because cancer patients are individuals



Clinical trial in colorectal cancer (TICC) – description of TICC protocol


TICC is an Investigator-Initiated-Trial (IIT) (NCT03251612 at www.clinicaltrials.gov)



*Univ. Hospital Vejle, DK
(Nominated best cancer hospital in DK for 6. time)*

Patients enrolled in TICC:

- Colorectal cancer patients with metastatic disease
- Tumors are growing (progressing) after treatment with all standard treatments



CT-scan of patient with liver metastases


Overall goal (Primary Endpoint) of TICC:

- No growth (Progression-Free-Survival, PFS) of liver metastases in 40% of the patients after eight weeks of IndiTreat-guided treatment (SOC is 20%)

IndiTreat® - a functional test monitoring drug efficacy and resistance

The IndiTreat® test measures drug sensitivity and resistance in each cancer patient


100s to 1000s copies (tumoroids) of patient's tumor



Tumoroids grow as in the patient

Tumor was resistant to Treatment A


Treatment B was highly effective – will be provided to patient




Patient-derived microtumors

- because cancer patients are individuals

IndiTreat[®] in the TICC trial




Patient



In full IndiTreat
screen the number of
off-label treatments
is larger

-because cancer patients are individuals

IndiTreat Colorectal Cancer Trial (TICC) met its Primary Endpoint



-because cancer patients are individuals

Early publication of results from colorectal cancer trial

The trial met the primary endpoint 

The full data is planned to be presented at ASCO Annual meeting

- ASCO (American Society of Clinical Oncology) is the largest and most prestigious worldwide congress on Clinical Oncology.
- ASCO is a perfect place for presenting these very important results.

Why a short press release ?

- Results submitted to the ASCO Annual meeting cannot be published prior to the meeting unless you are a **publicly traded company** where it is legally required to disclose certain data. Strict guidelines for such exceptional early publication:
 - the press release shall be short, only have qualitative information, no interpretations about the implications for clinical practice, and it shall follow a specific template



IndiTreat® movie at www.2curex.com



About IndiTreat® test

Investors

ABOUT 2CUREX

UPCOMING EVENTS

PARTNERS

Q&A

NEWS

CONTACT

The power of precision.
For every oncologist.
Today.

Every cancer patient deserves the right treatment
for their individual form of cancer.

NEW THE POWER OF PRECISION,
FOR EVERY ONCOLOGIST, TODAY

At 2cureX, we're pioneers of 3D
microtumors in cancer therapy,
focused on improving the outcomes of
cancer treatment

READ



Latest News


IndiTreat® clinical trial in colorectal cancer patients, TICC-1, meets its primary endpoint!

READ MORE

- because cancer patients are individuals




Colorectal Cancer – Market-Entry indication IndiTreat



- **Colorectal cancer** is the 2nd most common cancer in women and the 3rd most common in men.
- **Treatment** of Colorectal Cancer patients pose an everyday challenge for clinicians
- **IndiTreat®** will aid Clinical Oncologists in treatment decisions throughout the “Patient-Journey” of a colorectal cancer patient

-because cancer patients are individuals

Executing on our Commercial Roadmap in Europe



- Clinical Data milestone - important qualifier for commercial roll-out
- Colorectal Cancer as our market-entry indication translates to a significant market opportunity
- Commercial partnerships in several markets in place (green)
- Ramping up new distribution partnerships in other key launch markets (Grey)
- Transitioning to a commercial IVD company

Partnerships in place

Partnerships in progress

-because cancer patients are individuals

A solid Clinical and Commercial partner base in place

Group 1 Clinical trials Partners



Group 3 Patient societies



Group 2 Academic + Technical Partners



Group 4 Commercial Partners / Sales Channels

- because cancer patients are individuals

An attractive investment-case

- 2cureX is meeting an unmet medical need in cancer
- Strong momentum in the 2cureX story
- The IndiTreat[®] test improves PFS (Progression Free Survival) in colorectal cancer patients
- Strengthening the executive Management team with international go-to-market expertise
- First IndiTreat[®] product to be rolled-out
- Strong commercial outlook for 2021-2023
- An attractive investment-case

Follow us by signing up
for News on
www.2curex.com
and on:



Thank you for your attention !

- because cancer patients are individuals

- because cancer patients are individuals